Pfizer will be hiring around 80 new staffers for its new R&D campus now under construction — and this one is far from the two big hubs in the Bay Area and Boston/Cambridge that have proved so attractive to Big Pharma and biotech alike.
Pfizer $PFE will be bringing together 450 R&D staffers and adding its new roster in Chesterfield, MO — a St. Louis suburb — once they complete work on the $200 million project now underway. They’ll be working on new drugs that figure prominently on core fields in Pfizer’s pipeline: oncology, rare disease, internal medicine, inflammation & immunology, and vaccines, including biosimilars, which Pfizer has been focusing on since its Hospira buyout. And you can look for new work on manufacturing processes and dosage forms.
The open office plan, all the rage in new biopharma facilities, is being adopted here as the pharma giant also adds a substantial amount of new lab space.
The facility will become the new home to hundreds of workers scattered around the region, including some occupying rental space in Monsanto’s research center. Pfizer outlined its building plans last fall.
The new construction plans fit into a trend that’s been seeing big players like Merck, AstraZeneca, Pfizer and others migrating to big campuses. But this move falls well outside the geography that has dominated these moves for the past decade.
Image: rendering of Pfizer R&D facility site in Chesterfield, MO
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,000+ biopharma pros who read Endpoints News by email every day.Free Subscription